异基因造血干细胞移植 (HSCT) 是治疗多个亚型的白血病常用的方法。移植成功的关键因素之一就是移植者的细胞清除受体中残留的白血病，即移植物对白血病（GVL）的作用。而与此相反，移植过程中的常见并发症是移植物抗宿主病（GVHD），即捐赠者的细胞将受体各个器官系统视为外来物质，导致多种器官毒性反应，可以描述为自身免疫性。由于GVL和GVHD都通过类似的机制介导，这两个过程被认为是同时发生的。在这里，我们将回顾异基因HCT过程，并探讨GVL的相关内容。版权所有©2023 Elsevier Ltd. 保留所有权利。

Allogeneic hematopoietic stem cell transplantation (HSCT) is commonly utilized in the management of leukemia across multiple subtypes. Graft versus leukemia (GVL) is a critical component of successful transplantation and involves donor cells eradicating residual leukemia within the recipient. Graft versus host disease (GVHD) by contrast is a common complication of the transplantation process in which donor cells identify the recipient's various organ systems as foreign, thereby leading to a multitude of organ toxicities that can be described as autoimmune in nature. As both GVL and GVHD are mediated by a similar mechanism, these processes are felt to occur in tandem with one another. Here, we review the allogeneic HCT process in the context of GVL.Copyright © 2023 Elsevier Ltd. All rights reserved.